Approval · Notice of Compliance 38395 · 2026
TEVA-RISEDRONATE: Notice of Compliance 38395
Issued October 1, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38395
- Date
- October 1, 2026
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to package insert. Update to package labels
- Canadian reference product
- ACTONEL (Procter & Gamble Pharmaceuticals Canada, Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-RISEDRONATE | Not yet assigned | — |
Medicinal ingredients
- RISEDRONATE SODIUM 5 MG per TAB
- RISEDRONATE SODIUM 35 MG per TAB
- RISEDRONATE SODIUM 150 MG per TAB